Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEBL-Chimeric antigen receptor T cell therapy - MediSix Therapeutics/Twist Bioscience

Next Previous
Drug Profile

PEBL-Chimeric antigen receptor T cell therapy - MediSix Therapeutics/Twist Bioscience

Alternative Names: Research programme: Chimeric antigen receptor T cell therapies - MediSix Therapeutics/Twist Bioscience

Latest Information Update: 18 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MediSix Therapeutics; Twist Bioscience
  • Class Antibodies; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Precursor B-cell lymphoblastic leukaemia-lymphoma
  • No development reported Autoimmune disorders; Cancer

Most Recent Events

  • 13 Aug 2026 MediSix Therapeutics has been acquired by Nanjing IASO Biotechnology
  • 28 May 2026 No recent reports of development identified for research development in Autoimmune-disorders in Singapore (Parenteral)
  • 28 May 2026 No recent reports of development identified for research development in Cancer in Singapore (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top